Your browser is no longer supported. Please, upgrade your browser.
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.00 Insider Own0.20% Shs Outstand62.14M Perf Week-7.02%
Market Cap3.09B Forward P/E- EPS next Y-3.60 Insider Trans-25.42% Shs Float61.04M Perf Month-25.53%
Income-116.00M PEG- EPS next Q-0.74 Inst Own75.10% Short Float16.12% Perf Quarter45.79%
Sales90.70M P/S34.03 EPS this Y-14.60% Inst Trans-2.83% Short Ratio3.05 Perf Half Y30.69%
Book/sh7.10 P/B6.44 EPS next Y-7.50% ROA-23.70% Target Price54.83 Perf Year101.10%
Cash/sh7.33 P/C6.23 EPS next 5Y- ROE-38.70% 52W Range14.01 - 99.95 Perf YTD-34.83%
Dividend- P/FCF- EPS past 5Y-46.80% ROI-53.70% 52W High-56.00% Beta2.06
Dividend %- Quick Ratio9.20 Sales past 5Y- Gross Margin- 52W Low213.92% ATR4.86
Employees208 Current Ratio9.20 Sales Q/Q-7.00% Oper. Margin- RSI (14)31.64 Volatility9.31% 8.44%
OptionableYes Debt/Eq0.00 EPS Q/Q118.90% Profit Margin- Rel Volume0.70 Prev Close45.69
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 BMO Payout- Avg Volume3.23M Price43.98
Recom2.70 SMA20-21.68% SMA50-33.72% SMA2007.42% Volume2,058,599 Change-3.74%
Mar-01-21Downgrade Barclays Overweight → Equal Weight $46
Feb-26-21Downgrade Truist Buy → Hold $45
Jan-19-21Downgrade Morgan Stanley Equal-Weight → Underweight $64 → $45
Jan-07-21Downgrade Raymond James Outperform → Mkt Perform
Dec-10-20Upgrade Wells Fargo Equal Weight → Overweight $69
Nov-03-20Initiated Robert W. Baird Underperform $14
Jun-18-20Resumed SunTrust Buy $45
Feb-21-20Initiated Wells Fargo Equal Weight $28
Apr-12-19Initiated Evercore ISI Outperform
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Outperform $40
May-15-18Reiterated Chardan Capital Markets Buy $72.50 → $55
Feb-13-18Initiated CLSA Underperform
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-27-21 09:23AM  
Feb-26-21 09:04AM  
Feb-25-21 01:00PM  
Feb-23-21 02:29PM  
Feb-20-21 09:03AM  
Feb-18-21 04:02PM  
Feb-17-21 06:30AM  
Feb-12-21 05:45PM  
Feb-10-21 04:42PM  
Feb-08-21 08:00AM  
Feb-05-21 06:10AM  
Feb-04-21 05:45PM  
Jan-26-21 06:30AM  
Jan-25-21 05:45PM  
Jan-24-21 07:10AM  
Jan-20-21 11:31PM  
Jan-19-21 04:01PM  
Jan-18-21 08:41AM  
Jan-15-21 06:12PM  
Jan-14-21 03:11PM  
Jan-12-21 01:24PM  
Jan-11-21 12:20PM  
Jan-08-21 09:01AM  
Jan-07-21 04:24PM  
Jan-06-21 11:00AM  
Jan-05-21 06:23AM  
Jan-04-21 04:05PM  
Dec-31-20 11:43PM  
Dec-29-20 12:27PM  
Dec-24-20 11:10AM  
Dec-23-20 07:29PM  
Dec-22-20 09:58AM  
Dec-21-20 04:24PM  
Dec-17-20 04:05PM  
Dec-16-20 06:47PM  
Dec-14-20 01:58PM  
Dec-10-20 02:03PM  
Dec-09-20 04:01PM  
Dec-08-20 03:41PM  
Dec-07-20 11:41AM  
Dec-05-20 11:32AM  
Nov-10-20 04:01PM  
Nov-09-20 04:05PM  
Nov-07-20 09:06AM  
Nov-06-20 03:30PM  
Nov-05-20 05:25PM  
Nov-02-20 10:31AM  
Oct-29-20 04:01PM  
Oct-21-20 10:23AM  
Oct-13-20 09:45AM  
Oct-12-20 09:45AM  
Oct-10-20 09:55AM  
Oct-07-20 10:04AM  
Oct-06-20 07:45PM  
Sep-30-20 06:45AM  
Sep-18-20 06:43PM  
Sep-11-20 07:00AM  
Sep-05-20 11:32AM  
Sep-04-20 08:00AM  
Aug-26-20 11:54AM  
Aug-25-20 11:54AM  
Aug-24-20 08:30AM  
Aug-10-20 11:54AM  
Aug-06-20 04:05PM  
Jul-30-20 12:33PM  
Jul-29-20 08:00AM  
Jul-27-20 04:01PM  
Jul-25-20 11:52AM  
Jul-23-20 04:01PM  
Jul-21-20 07:07AM  
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Collins CynthiaCEOFeb 09Sale66.651,26284,11243,760Feb 10 04:26 PM
ROBERTSON MICHELLEChief Financial OfficerJan 12Sale78.271,568122,72718,432Jan 13 04:11 PM
Albright CharlesEVP/Chief Scientific OfficerDec 15Option Exercise16.5110,000165,10034,907Dec 17 06:58 PM
Albright CharlesEVP/Chief Scientific OfficerDec 15Sale63.2210,000632,15624,907Dec 17 06:58 PM
Albright CharlesEVP/Chief Scientific OfficerDec 09Option Exercise16.5110,000165,10034,907Dec 11 04:14 PM
Albright CharlesEVP/Chief Scientific OfficerDec 09Sale45.0010,000450,00024,907Dec 11 04:14 PM
Albright CharlesEVP/Chief Scientific OfficerDec 07Option Exercise16.5120,000330,20044,907Dec 08 04:12 PM
Albright CharlesEVP/Chief Scientific OfficerDec 07Sale40.0220,000800,40024,907Dec 08 04:12 PM
Albright CharlesEVP/Chief Scientific OfficerNov 09Sale31.212287,11624,907Nov 10 04:13 PM
Albright CharlesEVP/Chief Scientific OfficerOct 15Sale31.393,00094,17025,135Oct 16 04:38 PM
Collins CynthiaCEOAug 20Sale36.661,97672,44045,022Aug 21 04:12 PM
Albright CharlesEVP/Chief Scientific OfficerAug 17Option Exercise16.5110,000165,10038,135Aug 19 04:44 PM
Albright CharlesEVP/Chief Scientific OfficerAug 17Sale35.2910,000352,90028,135Aug 19 04:44 PM
Albright CharlesEVP/Chief Scientific OfficerAug 07Sale34.992388,32828,135Aug 10 04:24 PM
Albright CharlesEVP/Chief Scientific OfficerAug 06Option Exercise16.5110,000165,10038,373Aug 10 04:24 PM
Albright CharlesEVP/Chief Scientific OfficerAug 06Sale37.4710,000374,70028,373Aug 10 04:24 PM
Albright CharlesEVP/Chief Scientific OfficerJul 15Sale32.223,00096,66028,373Jul 17 05:32 PM
Albright CharlesEVP/Chief Scientific OfficerMay 06Sale25.281513,81731,373May 08 04:17 PM